Skip to main content
SpringerLink
Log in

Anti-TNF-α Antibody and Cancer Cachexia

  • Chapter
Cachexia and Wasting: A Modern Approach

  • 2152 Accesses

Abstract

Cachexia is characterised by accelerated loss of adipose tissue and skeletal muscle in the context of a chronic inflammatory response [1] [3]. It is a common complication of advanced cancer [4]. About half of all cancer patients suffer from this syndrome, which is among the most debilitating and life-threatening complications [5]. The key feature of this syndrome is weight loss, but other symptoms, such as anorexia, fatigue, vomiting and anaemia, and accelerated malnutrition with depletion of whole-body lipid and protein stores are frequently observed. Cancer cachexia contributes to immobility, a propensity to infection, shortened duration of survival, and overall decreased quality of life [6].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 189.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 249.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 329.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Tisdale MJ (2000) Biomedicine. Protein loss in cancer cachexia. Science 289:2293–2294

    Article  PubMed  CAS  Google Scholar 

  2. Kotler DP (2000) Cachexia. Ann Intern Med 133:622–634

    PubMed  CAS  Google Scholar 

  3. Ross JA, Fearon KC (2002) Eicosanoid-dependent cancer cachexia and wasting. Curr Opin Clin Nutr Metab Care 5:241–248

    Article  PubMed  CAS  Google Scholar 

  4. Fearon KC, Moses AG (2002) Cancer cachexia. Int J Cardiol 85:73–81

    Article  PubMed  Google Scholar 

  5. Inui A (2002) Cancer anorexia-cachexia syndrome: current issues in research and management. CA Cancer J Clin 52:72–91

    Article  PubMed  Google Scholar 

  6. Wigmore SJ, Ross JA, Falconer JS et al (1996) The effect of polyunsaturated fatty acids on the progress of cachexia in patients with pancreatic cancer. Nutrition 12:S27–S30

    PubMed  CAS  Google Scholar 

  7. Pirisi A (2000) US researchers find key link in muscle-wasting syndrome. Lancet 356:1249

    Article  PubMed  CAS  Google Scholar 

  8. McGeer AJ, Detsky AS, O’Rourke K (1990) Parenteral nutrition in cancer patients undergoing chemotherapy: a meta-analysis. Nutrition 6:233–240

    PubMed  CAS  Google Scholar 

  9. Balkwill F (2002) Tumor necrosis factor or tumor promoting factor? Cytokine Growth Factor Rev 13:135–141

    Article  PubMed  CAS  Google Scholar 

  10. Szlosarek PW, Balkwill FR (2003) Tumour necrosis factor alpha: a potential target for the therapy of solid tumours. Lancet Oncol 4:565–573

    Article  PubMed  CAS  Google Scholar 

  11. Anonymous (2004) Fact or fiction: biochemistry to the rescue. Lancet Oncol 5:197

    Article  Google Scholar 

  12. Mann M (1999) Approved pharmacologic interventions for wasting: an overview and lessons learned. J Nutr 129:303S–305S

    PubMed  CAS  Google Scholar 

  13. MacDonald N, Easson AM, Mazurak VC et al (2003) Understanding and managing cancer cachexia. J Am Coll Surg 197:143–161

    Article  PubMed  Google Scholar 

  14. Falconer JS, Fearon KC, Ross JA et al (1995) Acutephase protein response and survival duration of patients with pancreatic cancer. Cancer 75:2077–2082

    Article  PubMed  CAS  Google Scholar 

  15. Wigmore SJ, Plester CE, Richardson RA et al (1997) Changes in nutritional status associated with unresectable pancreatic cancer. Br J Cancer 75:106–109

    PubMed  CAS  Google Scholar 

  16. Andreyev HJ, Norman AR, Oates J et al (1998) Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies? Eur J Cancer 34:503–509

    Article  PubMed  CAS  Google Scholar 

  17. Kern S, Hruban R, Hollingsworth MA et al (2001) A white paper: the product of a pancreas cancer think tank. Cancer Res 61:4923–4932

    PubMed  CAS  Google Scholar 

  18. Tamura S, Ouchi KF, Mori K et al (1995) Involvement of human interleukin 6 in experimental cachexia induced by a human uterine cervical carcinoma xenograft. Clin Cancer Res 1:1353–1358

    PubMed  CAS  Google Scholar 

  19. Oliff A, Defeo-Jones D, Boyer M et al (1987) Tumors secreting human TNF/cachectin induce cachexia in mice. Cell 50:555–563

    Article  PubMed  CAS  Google Scholar 

  20. Sharma R, Anker SD (2002) Cytokines, apoptosis and cachexia:the potential for TNF antagonism. Int J Cardiol 85:161–171

    Article  PubMed  Google Scholar 

  21. Argiles JM, Moore-Carrasco R, Busquets S et al (2003) Catabolic mediators as targets for cancer cachexia. Drug Discov Today 8:838–844

    Article  PubMed  CAS  Google Scholar 

  22. Rouzer CA, Cerami A (1980) Hypertriglyceridemia associated with Trypanosoma brucei brucei infection in rabbits: role of defective triglyceride removal. Mol Biochem Parasitai 2:31–38

    Article  CAS  Google Scholar 

  23. Beutler B, Greenwald D, Hulmes JD et al (1985) Identity of tumour necrosis factor and the macrophage-secreted factor cachectin. Nature 316:552–554

    Article  PubMed  CAS  Google Scholar 

  24. Tracey KJ, Wei H, Manogue KR et al (1988) Cachectin/tumor necrosis factor induces cachexia, anemia, and inflammation. J Exp Med 167:1211–1227

    Article  PubMed  CAS  Google Scholar 

  25. Darling G, Fraker DL, Jensen JC et al (1990) Cachectic effects of recombinant human tumor necrosis factor in rats. Cancer Res 50:4008–4013

    PubMed  CAS  Google Scholar 

  26. Llovera M, Lopez-Soriano FJ, Argiles JM (1993) Effects of tumor necrosis factor-alpha on muscle-protein turnover in female Wistar rats. J Natl Cancer Inst 85:1334–1339

    Article  PubMed  CAS  Google Scholar 

  27. Llovera M, Garcia-Martinez C, Lopez-Soriano J et al (1998) Protein turnover in skeletal muscle of tumour-bearing transgenic mice overexpressing the soluble TNF receptor-1. Cancer Lett 130:19–27

    Article  PubMed  CAS  Google Scholar 

  28. Guttridge DC, Mayo MW, Madrid LV et al (2000) NFkappaB-induced loss of MyoD messenger RNA: possible role in muscle decay and cachexia. Science 289:2363–2366

    Article  PubMed  CAS  Google Scholar 

  29. Megeney LA, Kablar B, Garrett K et al (1996) MyoD is required for myogenic stem cell function in adult skeletal muscle. Genes Dev 10:1173–1183

    Article  PubMed  CAS  Google Scholar 

  30. Argiles JM, Lopez-Soriano J, Busquets S et al (1997) Journey from cachexia to obesity by TNF. FASEB J 11:743–751

    PubMed  CAS  Google Scholar 

  31. Bossola M, Muscaritoli M, Bellantone R et al (2000) Serum tumour necrosis factor-alpha levels in cancer patients are discontinuous and correlate with weight loss. Eur J Clin Invest 30:1107–1112

    Article  PubMed  CAS  Google Scholar 

  32. Mantovani G, Macciò A, Mura L et al (2000) Serum levels of leptin and proinflammatory cytokines in patients with advanced-stage cancer at different sites. J Mol Med 78:554–561

    Article  PubMed  CAS  Google Scholar 

  33. Nakashima J, Tachibana M, Ueno M et al (1998) Association between tumor necrosis factor in serum and cachexia in patients with prostate cancer. Clin Cancer Res 4:1743–1748

    PubMed  CAS  Google Scholar 

  34. Falconer JS, Fearon KC, Plester CE et al (1994) Cytokines, the acute-phase response, and resting energy expenditure in cachectic patients with pancreatic cancer. Ann Surg 219:325–331

    Article  PubMed  CAS  Google Scholar 

  35. Karayiannakis AJ, Syrigos KN, Polychronidis A et al (2001) Serum levels of tumor necrosis factor-alpha and nutritional status in pancreatic cancer patients. Anticancer Res 21:1355–1358

    PubMed  CAS  Google Scholar 

  36. Sherry BA, Gelin J, Fong Y et al (1989) Anticachectin/tumor necrosis factor-alpha antibodies attenuate development of cachexia in tumor models. FASEBJ 3:1956–1962

    CAS  Google Scholar 

  37. Trikha M (2002) Combined blockade of human and mouse TNF inhibits cancer cachexia in nude mice. Centocor Technical Report Biorestr 315 (Internal Centocor Report), Centocor Inc, Malvern

    Google Scholar 

  38. Siegel SA, Shealy DJ, Nakada MT et al (1995) The mouse/human chimeric monoclonal antibody cA2 neutralizes TNF in vitro and protects transgenic mice from cachexia and TNF lethality in vivo. Cytokine 7:15–25

    Article  PubMed  CAS  Google Scholar 

  39. Torelli GF, Meguid MM, Moldawer LL et al (1999) Use of recombinant human soluble TNF receptor in anorectic tumor-bearing rats. Am J Physiol 277:R850–R855

    PubMed  CAS  Google Scholar 

  40. Truyens C, Torrico F, Angelo-Barrios A et al (1995) The cachexia associated with Trypanosoma cruzi acute infection in mice is attenuated by anti-TNF-alpha,but not by anti-IL-6 or anti-IFN-gamma antibodies. Parasite Immunol 17:561–568

    PubMed  CAS  Google Scholar 

  41. Haslett PA (1998) Anticytokine approaches to the treatment of anorexia and cachexia. Semin Oncol 25:53–57

    PubMed  CAS  Google Scholar 

  42. Steensma DP, Mesa RA, Li CY et al (2002) Etanercept, a soluble tumor necrosis factor receptor, palliates constitutional symptoms in patients with myelofibrosis with myeloid metaplasia: results of a pilot study. Blood 99:2252–2254

    Article  PubMed  CAS  Google Scholar 

  43. Fonseca J, Canhao H, Resende C et al (2002) Weight gain associated with the administration of tumor necrosis factor alpha antagonists in patients with rheumatoid arthritis. EULAR (Annual European Congress of Rheumatology). Arthritis Reum 46:S170 (abs)

    Google Scholar 

  44. Eggermont AM, de Wilt JH, ten Hagen TL (2003) Current uses of isolated limb perfusion in the clinic and a model system for new strategies. Lancet Oncol 4:429–437

    Article  PubMed  Google Scholar 

  45. Eggermont AM, ten Hagen TL (2003) Tumor necrosis factor-based isolated limb perfusion for soft tissue sarcoma and melanoma: ten years of successful antivascular therapy. Curr Oncol Rep 5:79–80

    Article  PubMed  Google Scholar 

  46. Arnott CH, Scott KA, Moore RJ et al (2004) Expression of both TNF-alpha receptor subtypes is essential for optimal skin tumour development. Oncogene 23:1902–1910

    Article  PubMed  CAS  Google Scholar 

  47. Malik ST, Griffin DB, Fiers W et al (1989) Paradoxical effects of tumour necrosis factor in experimental ovarian cancer. Int J Cancer 44:918–925

    Article  PubMed  CAS  Google Scholar 

  48. Scott KA, Moore RJ, Arnott CH et al (2003) An anti-tumor necrosis factor-alpha antibody inhibits the development of experimental skin tumors. Mol Cancer Ther 2:445–451

    PubMed  CAS  Google Scholar 

  49. Montserrat E (1997) Chronic lymphoproliferative disorders. Curr Opin Oncol 9:34–41

    PubMed  CAS  Google Scholar 

  50. Holden RJ, Pakula IS, Mooney PA (1998) An immunological model connecting the pathogenesis of stress, depression and carcinoma. Med Hypotheses 51:309–314

    Article  PubMed  CAS  Google Scholar 

  51. Tselepis C, Perry I, Dawson C et al (2002) Tumour necrosis factor-alpha in Barrett’s oesophagus: a potential novel mechanism of action. Oncogene 21:6071–6081

    Article  PubMed  CAS  Google Scholar 

  52. Barak V, Nisman B, Polliack A (1999) The tumor necrosis factor family and correlation with disease activity and response to treatment in hairy cell leukemia. Eur J Haematol 62:71–75

    Article  PubMed  CAS  Google Scholar 

  53. Schiller JH, Bittner G, Spriggs DR (1992) Tumor necrosis factor,but not other hematopoietic growth factors, prolongs the survival of hairy cell leukemia cells. Leuk Res 16:337–346

    Article  PubMed  CAS  Google Scholar 

  54. Hideshima T, Chauhan D, Schlossman R et al (2001) The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications. Oncogene 20:4519–4527

    Article  PubMed  CAS  Google Scholar 

  55. Foa R, Massaia M, Cardona S et al (1990) Production of tumor necrosis factor-alpha by B-cell chronic lymphocytic leukemia cells: a possible regulatory role of TNF in the progression of the disease. Blood 76:393–400

    PubMed  CAS  Google Scholar 

  56. Huang D, Reittie JE, Stephens S et al (1992) Effects of anti-TNF monoclonal antibody infusion in patients with hairy cell leukaemia. Br J Haematol 81:231–234

    PubMed  CAS  Google Scholar 

  57. Friess H, Guo XZ, Nan BC et al (1999) Growth factors and cytokines in pancreatic carcinogenesis. Ann NY Acad Sci 880:110–121

    Article  PubMed  CAS  Google Scholar 

  58. Cope AP, Londei M, Chu NR et al (1994) Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor/CD3 complex; reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis. J Clin Invest 94:749–760

    Article  PubMed  CAS  Google Scholar 

  59. D’Haens G, Ceuppens J, Colpaert S et al (1997) Restoration of decreased in vitro lymphocyte proliferative response to mycobacteria and mitogens after single infusion of chimeric anti-TNF alpha antibodies in Crohn’s disease. Gastroenterology 112:A595 (abs)

    Article  Google Scholar 

  60. Meenan J, Hommes D, van Dullemen H (1997) The influence of TNF alpha mAb, cA2, on circulating lymphocyte populations. Gastroenterology 112:A1039 (abs)

    Article  Google Scholar 

  61. Knight DM, Trinh H, Le J et al (1993) Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol 30:1443–1453

    Article  PubMed  CAS  Google Scholar 

  62. Nahar IK, Shojania K, Marra CA et al (2003) Infliximab treatment of rheumatoid arthritis and Crohn’s disease. Ann Pharmacother 37:1256–1265

    Article  PubMed  CAS  Google Scholar 

  63. Hommes DW, van Deventer SJ (2003) Infliximab therapy in Crohn’s disease:safety issues. Neth J Med 61:100–104

    PubMed  CAS  Google Scholar 

  64. Mikuls TR, Moreland LW (2003) Benefit-risk assessment of infliximab in the treatment of rheumatoid arthritis. Drug Saf 26:23–32

    Article  PubMed  CAS  Google Scholar 

  65. Khanna D, McMahon M, Furst DE (2004) Safety of tumour necrosis factor-alpha antagonists. Drug Saf 27:307–324

    Article  PubMed  CAS  Google Scholar 

  66. Anonymous (2003) REMICADE® (infliximab) package insert. Centocor Inc, Malvern

    Google Scholar 

  67. Marty FM, Lee SJ, Fahey MM et al (2003) Infliximab use in patients with severe graft-versus-host disease and other emerging risk factors of non-Candida invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients: a cohort study. Blood 102:2768–2776

    Article  PubMed  CAS  Google Scholar 

  68. Smith KJ, Skelton HG (2001) Rapid onset of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis after starting tumor necrosis factor alpha receptor IgGl-Fc fusion complex therapy. J Am Acad Dermatol 45:953–956

    Article  PubMed  CAS  Google Scholar 

  69. Kavanaugh A, Keystone EC (2003) The safety of biologic agents in early rheumatoid arthritis. Clin Exp Rheumatol 21:S203–S208 (abs)

    PubMed  CAS  Google Scholar 

  70. Wolfe F, Michaud K (2003) Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-TNF therapy in 18,572 patients. Arthritis Rheum 48:S242 (abs)

    Google Scholar 

  71. Lee JH, Slifman NR, Gershon SK et al (2002) Lifethreatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept. Arthritis Rheum 46:2565–2570

    Article  PubMed  CAS  Google Scholar 

  72. Brown SL, Greene MH, Gershon SK et al (2002) Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum 46:3151–3158

    Article  PubMed  CAS  Google Scholar 

  73. Slifman NR, Gershon SK, Lee JH et al (2003) Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents. Arthritis Rheum 48:319–324

    Article  PubMed  CAS  Google Scholar 

  74. Colombel JF, Loftus EVJr, Tremaine WJ et al (2004) The safety profile of infliximab in patients with Crohn’s disease: the Mayo clinic experience in 500 patients. Gastroenterology 126:19–31

    Article  PubMed  CAS  Google Scholar 

  75. Ramesh G, Reeves WB (2002) TNF-alpha mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity. J Clin Invest 110:835–842

    Article  PubMed  CAS  Google Scholar 

  76. Delanian S, Porcher R, Balla-Mekias S et al (2003) Randomized, placebo-controlled trial of combined pentoxifylline and tocopherol for regression of superficial radiation-induced fibrosis. J Clin Oncol 21:2545–2550

    Article  PubMed  CAS  Google Scholar 

  77. Rube CE, van Valen F, Wilfert F et al (2003) Ewing’s sarcoma and peripheral primitive neuroectodermal tumor cells produce large quantities of bioactive tumor necrosis factor-alpha (TNF-alpha) after radiation exposure. Int J Radiat Oncol Biol Phys 56:1414–1425

    Article  PubMed  CAS  Google Scholar 

  78. Azuma Y, Kaji K, Katogi R et al (2000) Tumor necrosis factor-alpha induces differentiation of and bone résorption by osteoclasts. J Biol Chem 275:4858–4864

    Article  PubMed  CAS  Google Scholar 

  79. Schafers M, Lee DH, Brors D et al (2003) Increased sensitivity of injured and adjacent uninjured rat primary sensory neurons to exogenous tumor necrosis factoralpha after spinal nerve ligation. J Neurosci 23:3028–3038

    PubMed  CAS  Google Scholar 

  80. Tobinick EL (2003) Targeted etanercept for treatment-refractory pain due to bone metastasis: two case reports. Clin Ther 25:2279–2288

    Article  PubMed  Google Scholar 

  81. Anonymous (2002) American Thoracic Society statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 166:111–117

    Google Scholar 

  82. Cella D, Eton DT, Lai JS et al (2002) Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales. J Pain Symptom Manage 24:547–561

    Article  PubMed  Google Scholar 

  83. Johnson JR, Williams G, Pazdur R (2003) End points and United States Food and Drug Administration approval of oncology drugs. J Clin Oncol 21:1404–1411

    Article  PubMed  Google Scholar 

  84. Steer CB, Marx GM, Harper PG (2001) Is there quality in clinical benefit? Ann Oncol 12:1191–1193

    Article  PubMed  CAS  Google Scholar 

  85. Patrick-Miller LJ (2003) Is there a role for the assessment of health-related quality of life in the clinical evaluation of novel cytostatic agents? Clin Cancer Res 9:2040–2048 Commentary re: LoRusso PM (2003) Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors. Clin Cancer Res 9:1990-1994

    Google Scholar 

  86. Cleeland CS, Bennett GJ, Dantzer R et al (2003) Are the symptoms of cancer and cancer treatment due to a shared biologic mechanism? A cytokineimmunologic model of cancer symptoms. Cancer 97:2919–2925

    Article  PubMed  Google Scholar 

  87. Pfitzenmaier J, Vessella R, Higano CS et al (2003) Elevation of cytokine levels in cachectic patients with prostate carcinoma. Cancer 97:1211–1216

    Article  PubMed  CAS  Google Scholar 

  88. Raison CL, Miller AH (2003) Depression in cancer: new developments regarding diagnosis and treatment. Biol Psychiatry 54:283–294

    Article  PubMed  Google Scholar 

  89. Chassany O, Sagnier P, Marquis P et al (2002) Patient reported outcomes: the example of health-related quality of life. A European guidance document for the improved integration of health-related quality of life assessments in the drug regulatory process. Drug Inf J 36:209–238

    Google Scholar 

  90. Hirschfeld S, Pazdur R (2002) Oncology drug development: United States Food and Drug Administration perspective. Crit Rev Oncol Hematol 42:137–143

    Article  PubMed  Google Scholar 

  91. Revicki DA, Osoba D, Fairclough D et al (2000) Recommendations on health-related quality of life research to support labeling and promotional claims in the United States. Qual Life Res 9:887–900

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clinical Hematology/Oncology, Centocor, Malvern, PA, USA

    Mark de Witte, Mark Anderson & Don Robinson

Authors
  1. Mark de Witte
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mark Anderson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Don Robinson
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Medical Oncology, University of Cagliari, Cagliari, Italy

    Giovanni Mantovani

  2. Department of Clinical Cardiology, Imperial College, NHLI, London, UK

    Stefan D. Anker

  3. Department of Cardiology Charité, Applied Cachexia Research, Campus Virchow-Klinikum, Berlin, Germany

    Stefan D. Anker

  4. Department of Behavioral Medicine, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan

    Akio Inui

  5. GRECC, VA Medical Center and Division of Geriatric Medicine, Saint Louis University, St. Louis, MO, USA

    John E. Morley

  6. Department of Clinical Medicine, University of Rome, La Sapienza, Rome, Italy

    Filippo Rossi Fanelli

  7. Department of Infectious Diseases, IRCCS S.Matteo Polyclinic, University of Pavia, Pavia, Italy

    Daniele Scevola

  8. Bone Marrow and Blood Stem Cell Transplantation Program, Center for Lymphoma and Myeloma, New York Presbyterian Hospital/Weill Medical Center, New York, NY, USA

    Michael W. Schuster

  9. Department of Medicine-Geriatrics, University of New York at Stony Brook VAMC, Northport, NY, USA

    Shing-Shing Yeh

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Springer-Verlag Italia

About this chapter

Cite this chapter

de Witte, M., Anderson, M., Robinson, D. (2006). Anti-TNF-α Antibody and Cancer Cachexia. In: Mantovani, G., et al. Cachexia and Wasting: A Modern Approach. Springer, Milano. https://doi.org/10.1007/978-88-470-0552-5_66

Download citation

  • DOI: https://doi.org/10.1007/978-88-470-0552-5_66

  • Publisher Name: Springer, Milano

  • Print ISBN: 978-88-470-0471-9

  • Online ISBN: 978-88-470-0552-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation